Mazzaneh
Phase 1 provides real product, market, merchant, user-interaction and commerce context from a bounded MVP period. It is historical operating evidence, not a claim of current transferable market scale.
Review Phase 1 →MZN is a founder-led technology and AI portfolio organized around a simple discipline: preserve how each asset was formed, distinguish what has actually been built or tested from what still requires independent validation, and let programs and assets advance through the review path appropriate to them.
MZN should not be read as a single product, a single research program, or a single claim. It connects operating product history, an AI-native formation period, technical and research assets, and current Phase 3 programs without erasing the boundary between them.
Phase 1 provides real product, market, merchant, user-interaction and commerce context from a bounded MVP period. It is historical operating evidence, not a claim of current transferable market scale.
Review Phase 1 →A bounded solo formation period produced a broad mapped portfolio spanning product, AI infrastructure, optimization, security, evaluation, architecture and research assets with distinct maturity states.
Review Phase 2 →Phase 3 is the open professionalization layer: validate, rebuild, pilot, partner, license, commercialize or independently advance the relevant object without forcing the entire portfolio into one route.
Open Phase 3 →Phase does not define every future use of an asset. A Phase 2-origin technical system can enter an independent Phase 3 licensing route. A Phase 1 product can be rebuilt for a new market. Cross-phase integration is possible without rewriting provenance.
Mazzaneh and selected modules were built and operated with a human execution team. Phase 1 is product, market and operating evidence—not the solo provenance claim.
Phase 1 →The One-Person Unicorn provenance question is bounded here. Asset existence, provenance, maturity, novelty and strategic value remain distinct evaluation dimensions.
Phase 2 →Technical validation, legal/IP review, pilots, selective engineering, commercialization, research collaboration and partner selection belong here.
Phase 3 →A serious counterparty does not need to enter the entire portfolio. Programs and assets can stand alone, form clusters, or selectively converge where the integration creates real value.
New-market relaunch informed by Phase 1 operating evidence, not dependent on the historical Iranian user base.
Phase 3 human-facing intelligence product with earlier conceptual lineage and optional convergence paths.
Cross-phase human-context intelligence architecture with Phase 3 operationalization.
Technical assets and clusters can enter validation, licensing, pilot, research or commercialization routes independently.
A bounded Phase 2 provenance and strategic-substance case that can continue to be challenged without extending the solo boundary.
BioCode, HDTP, ISBP and related foundational or applied research routes remain reviewable on their own terms.
The public site is a live pitch deck and review surface. It explains architecture, boundaries, selected public evidence, maturity states and review paths.
It is not an unrestricted data room and does not claim that every non-public record has already received independent validation.
For material questions, the evidence path escalates rather than forcing unrestricted publication. Public absence of sensitive source records is not proof of absence; the existence of a source category is also not proof of independent validation.
Partnership is the primary route for strategic conversations. General and alternate email routes are available for company-level inquiries and delivery fallback.